Aortic Valve Calcification Inhibition Using Prazole Compounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for aortic valve calcification, such as valve replacement, are invasive and require lifelong anticoagulation, while drug therapies for preventing calcification progression are lacking.
Innovation Solution
The use of proton pump inhibitors, particularly prazole compounds like rabeprazole, omeprazole, lansoprazole, pantoprazole, and esomeprazole, to inhibit or prevent aortic valve calcification through administration to subjects at risk or with early signs of calcification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If valve replacement is performed to treat aortic valve calcification, then valve function is restored, but the treatment becomes invasive and requires lifelong anticoagulation
Solution Approach 1:
The patent replaces the mechanical intervention of valve replacement surgery with a pharmacological approach using proton pump inhibitors. These drugs inhibit the proton pump in osteoclasts, preventing bone formation in the valve tissue, thereby treating calcification through biochemical means rather than mechanical replacement.
Solution Approach 2:
The patent introduces proton pump inhibitors as an intermediary substance that mediates between the calcification process and the desired outcome. The drugs act as intermediaries by binding to and inhibiting the H+/K+-ATPase enzyme in osteoclasts, thereby preventing the calcification process without requiring direct mechanical intervention on the valve.
2Reliability
If mechanical valves are implanted to treat aortic stenosis, then valve function is restored, but lifelong anticoagulation therapy is required
Solution Approach 1:
The patent replaces the mechanical valve system with a pharmacological prevention system. Instead of implanting a mechanical device that requires lifelong anticoagulation, the treatment uses proton pump inhibitors to prevent further calcification progression, eliminating the need for anticoagulation therapy.
Solution Approach 2:
The patent extracts the problematic requirement for lifelong anticoagulation by avoiding mechanical valve implantation altogether. The solution removes the need for anticoagulation by treating the underlying calcification process with proton pump inhibitors rather than replacing the valve with a mechanical device.
3Ease of operation
If no drug therapy is used for aortic valve calcification, then treatment simplicity is maintained, but calcification progression continues unchecked
Solution Approach 1:
The patent enables the body's own regulatory mechanisms to work against calcification by using proton pump inhibitors that naturally inhibit osteoclast activity. The treatment leverages the body's existing cellular pathways, allowing the physiological system to self-regulate and prevent calcification progression without complex external intervention.
Data Source
AI summary
The present invention relates to compounds useful for inhibiting calcification of aortic valves and to the treatment of diseases including aortic sclerosis and stenosis, and in particular to the use of the proton pump inhibitors including prazole compounds for the aforesaid treatments.